 H.C. Wainwright lowered the price target on Eloxx Pharmaceuticals Inc NASDAQ: ELOX to 1 from 2 and reiterated a Neutral rating. Analyst Andrew Fein says the ELX-02 top-line data raises more questions than answers. 